Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06758401 |
Title | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02) |
Acronym | Be6A Lung-02 |
Recruitment | Not yet recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | Pfizer |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries |